Ein vielversprechendes immuntherapeutisches Vakzin zur Behandlung von Sarkoiden bei Pferden und anderen Equiden

Sarkoide sind sehr häufige Hauttumoren bei Pferden und anderen Equiden. Obwohl sie nicht metastasieren, stellen sie ein veterinärmedizinisch hochrelevantes Problem dar, da sie besonders in fortgeschrittenen Stadien äußerst therapieresistent sein können.

Publication History

Article published online:
25 March 2022

• Literatur

• 1 Hainisch EK, Brandt S. Equine Sarcoids. In: Robinson NE, Sprayberry KA. eds. Robinsonʼs Current Therapy in Equine Medicine, 7th ed. St. Louis, Missouri, USA: Saunders Elsevier; 2015: 424-427
• 2 Nasir L, Reid SWJ. Bovine papillomaviruses and equine sarcoids. In: Campo MS. ed. Papillomavirus Research: From Natural History to Vaccines and Beyond. 1st ed.. Norfolk, UK: Caister Academic Press; 2006: 389-397
• 3 Jindra C, Kamjunke AK, Jones S, Brandt S. Screening for bovine papillomavirus type 13 (BPV13) in a European population of sarcoid-bearing equids. Equine Vet J 2021; DOI: 10.1111/evj.13501.
• 4 Lunardi M, Alcantara BK de Otonel RA. et al. Bovine papillomavirus type 13 DNA in equine sarcoids. J Clin Microbiol 2013; 51: 2167-2171
• 5 Yuan Z, Gault EA, Campo MS. et al. Different contribution of bovine papillomavirus type 1 oncoproteins to the transformation of equine fibroblasts. J Gen Virol 2011; 92: 773-783
• 6 Hartl B, Hainisch EK, Shafti-Keramat S. et al. Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation. J Gen Virol 2011; 92: 2437-2445
• 7 Campo MS. Bovine papillomavirus: old system, new lessons?. In: Campo MS. ed. Papillomavirus Research: From Natural History to Vaccines and Beyond. 1st ed.. Norfolk, UK: Caister Academic Press; 2006: 373-387
• 8 Marchetti B, Gault EA, Cortese MS. et al. Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain. J Gen Virol 2009; 90: 2865-2870
• 9 Haspeslagh M, Vlaminck LE, Martens AM. Treatment of sarcoids in equids: 230 cases (2008–2013). J Am Vet Med Assoc 2016; 249: 311-318
• 10 Knottenbelt DC. The Equine Sarcoid: Why Are There so Many Treatment Options?. Vet Clin North Am Equine Pract 2019; 35: 243-262
• 11 Gajewski TF. Cancer immunotherapy. Mol Oncol 2012; 6 (02) 242-250
• 12 Espy BMK. How to Treat Equine Sarcoids by Autologous Implantation. AAEP Proceedings 2008; 54: 68-73
• 13 Rothacker CC, Boyle AG, Levine DG. Autologous vaccination for the treatment of equine sarcoids: 18 cases (2009–2014). Can Vet J 2015; 56: 709-714
• 14 Egorov A, Brandt S, Sereinig S. et al. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol 1998; 72: 6437-6441
• 15 Garcia-Sastre A, Egorov A, Matassov D. et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998; 252: 324-330
• 16 Wolschek M, Samm E, Seper H. et al. Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency. J Virol 2011; 85: 2469-2473
• 17 Jindra C, Huber B, Shafti-Keramat S. et al. Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach. PLoS One 2015; 10: e0138722
• 18 Jindra C, Hainisch EK, Rümmele A, Wolschek M, Muster T, Brandt S. Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients. PLoS One 2021; DOI: 10.1371/journal.pone.0260155.